Roanoke Asset Management Corp NY Sells 1,275 Shares of Amgen Inc. (NASDAQ:AMGN)

Roanoke Asset Management Corp NY cut its stake in Amgen Inc. (NASDAQ:AMGN) by 5.1% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 23,693 shares of the medical research company’s stock after selling 1,275 shares during the period. Amgen comprises about 1.9% of Roanoke Asset Management Corp NY’s portfolio, making the stock its 17th largest position. Roanoke Asset Management Corp NY’s holdings in Amgen were worth $4,081,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Camelot Portfolios LLC acquired a new position in Amgen during the first quarter worth $1,429,000. Private Asset Management Inc. raised its position in Amgen by 117.8% in the first quarter. Private Asset Management Inc. now owns 3,591 shares of the medical research company’s stock worth $589,000 after buying an additional 1,942 shares during the period. Cadence Bank NA raised its position in Amgen by 6.2% in the first quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock worth $554,000 after buying an additional 197 shares during the period. Stillwater Capital Advisors LLC acquired a new position in Amgen during the first quarter worth $202,000. Finally, Kornitzer Capital Management Inc. KS raised its position in Amgen by 70.6% in the first quarter. Kornitzer Capital Management Inc. KS now owns 38,865 shares of the medical research company’s stock worth $6,377,000 after buying an additional 16,080 shares during the period. Institutional investors own 79.12% of the company’s stock.

Shares of Amgen Inc. (NASDAQ:AMGN) opened at 167.29 on Friday. The firm has a market capitalization of $122.07 billion, a price-to-earnings ratio of 15.24 and a beta of 1.35. The stock has a 50 day moving average of $174.04 and a 200 day moving average of $168.05. Amgen Inc. has a 52-week low of $133.64 and a 52-week high of $184.21.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. During the same quarter last year, the firm posted $2.84 EPS. The company’s quarterly revenue was up 2.1% on a year-over-year basis. On average, analysts predict that Amgen Inc. will post $12.57 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be issued a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date of this dividend is Tuesday, August 15th. Amgen’s dividend payout ratio is currently 41.93%.

COPYRIGHT VIOLATION WARNING: This news story was reported by BNB Daily and is the property of of BNB Daily. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/19/amgen-inc-nasdaqamgn-stake-reduced-by-roanoke-asset-management-corp-ny-updated.html.

Several analysts have recently commented on the stock. Mizuho set a $195.00 price target on shares of Amgen and gave the company a “buy” rating in a research report on Saturday, May 6th. UBS AG reaffirmed a “neutral” rating and set a $174.00 price target (down previously from $175.00) on shares of Amgen in a research report on Monday, May 22nd. Jefferies Group LLC reaffirmed a “buy” rating and set a $195.00 price target on shares of Amgen in a research report on Tuesday, July 11th. BMO Capital Markets reaffirmed a “buy” rating and set a $198.00 price target (down previously from $200.00) on shares of Amgen in a research report on Monday, May 22nd. Finally, Leerink Swann reiterated a “market perform” rating and issued a $161.00 target price on shares of Amgen in a report on Thursday, June 22nd. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $186.64.

In other news, SVP Cynthia M. Patton sold 2,922 shares of Amgen stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the sale, the senior vice president now owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.20% of the stock is currently owned by company insiders.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply